- Raw materials
- Antibacterials
- Tetracyclines
- Lymecycline
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Lymecycline API Manufacturers & Suppliers
5 verified results
Commercial-scale Suppliers
Employees: 475
All certificates
Employees: 200+
All certificates
Employees: 50
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Lymecycline | CAS No: 992-21-2 | GMP-certified suppliers
A medication that treats acne caused by susceptible bacteria and supports the management of various respiratory, urinary, and other bacterial infections for broad therapeutic use.
Therapeutic categories
Primary indications
- Lymecycline is used for the treatment of acne in addition to other susceptible infections
- Propionibacterium is often the cause of acne
- Some of the infections that can be treated with lymecycline include upper respiratory tract infections, urinary tract infections, bronchitis, chlamydial infections, and rickettsial infections
Product Snapshot
- Lymecycline is a small‑molecule tetracycline antibiotic supplied mainly as oral capsules with some intramuscular injectable forms
- It is used for acne driven by Cutibacterium acnes and a range of susceptible respiratory, urinary, chlamydial, and rickettsial infections
- It holds approved status in multiple markets with additional investigational use in some regions
Clinical Overview
Lymecycline belongs to the tetracycline class of polyketide antibiotics characterized by an octahydrotetracene‑2‑carboxamide core with multiple hydroxy substitutions. Its pharmacodynamic profile is consistent with other tetracyclines, producing bacteriostatic activity against intracellular and extracellular pathogens.
The mechanism of action involves binding to the 30S ribosomal subunit, blocking the attachment of aminoacyl‑tRNA to the A site of the mRNA‑ribosome complex. This inhibition prevents peptide chain elongation and halts bacterial protein synthesis, resulting in growth suppression rather than cell lysis.
Absorption is enhanced relative to older tetracyclines due to improved solubility, and systemic exposure supports once‑daily dosing in acne. Distribution is broad, with intracellular penetration characteristic of the class. Elimination occurs by renal and biliary pathways; reduced clearance may occur in renal or hepatic impairment, and use is generally avoided in severe dysfunction.
Safety considerations align with the tetracycline class. Esophageal irritation or ulceration may occur and can be mitigated by adequate fluid intake. Photosensitivity is a known risk. Renal tubular acidosis and hepatic toxicity have been reported, and use in patients with significant renal or hepatic disease is not recommended. As with related agents, use during tooth and bone development is generally avoided.
For API procurement, suppliers should provide evidence of compliance with regional GMP standards, validated impurity controls characteristic of tetracycline derivatives, and stability data supporting appropriate storage and transport conditions.
Identification & chemistry
| Generic name | Lymecycline |
|---|---|
| Molecule type | Small molecule |
| CAS | 992-21-2 |
| UNII | 7D6EM3S13P |
| DrugBank ID | DB00256 |
Pharmacology
| Summary | Lymecycline is a tetracycline-class antibacterial that binds the 30S ribosomal subunit, blocking aminoacyl‑tRNA attachment and inhibiting bacterial protein elongation. This action produces bacteriostatic effects against a range of intracellular and extracellular susceptible organisms, including those implicated in acne. Its pharmacologic activity centers on suppression of bacterial protein synthesis through targeted ribosomal interference. |
|---|---|
| Mechanism of action | Normally, the ribosome synthesizes proteins through the binding of aminoacyl-tRNA to the mRNA-ribosome complex. Lymecycline binds to the 30S ribosomal subunit, preventing amino-acyl tRNA from binding to the A site of the ribosome, which prevents the elongation of polypeptide chains.This results in bacteriostatic actions, treating various infections. |
| Pharmacodynamics | Lymecycline, like other tetracyclines, exerts bacteriostatic actions on intracellular and extracellular bacteria, treating susceptible bacterial infections.It has been shown to be safe and effective in the treatment of moderate to severe acne. It is important to note that like other tetracyclines, lymecycline may cause esophageal irritation and ulceration, which can be prevented by drinking adequate fluids during administration. It also has the potential to cause photosensitivity. Lymecycline can lead to renal tubular acidosis or hepatic toxicity. It is not recommended to administer this drug in patients with renal disease or severe hepatic disease. |
Targets
| Target | Organism | Actions |
|---|---|---|
| 30S ribosomal protein S4 | Escherichia coli (strain K12) | inhibitor |
ADME / PK
| Absorption | Lymecycline is 77-88% absorbed after oral administration with a relative bioavailability of 70%.The Cmax of lymecycline is 2.1 mg/L and is achieved about 3 hours after administration.The AUC is 21.9 ± 4.3 mg·h/L. |
|---|---|
| Half-life | The half-life of lymecycline is approximately 8 hours. |
| Route of elimination | Lymecycline is 25% eliminated in the urine.Based on being a member of the tetracycline drug class, fecal elimination is likely another route of elimination. |
| Volume of distribution | Lymecycline is lipophilic and easily crosses the cell membrane and passively diffuses through bacterial porin channels.As a second-generation tetracycline, the concentration in the bile ranges from 10 to 25 times higher than plasma concentration.In general, the volume of distribution of tetracyclines ranges from 1.3–1.7 L/kg or 100–130 L. |
| Clearance | Lymecycline is partially cleared by the kidneys, like other tetracyclines. |
Formulation & handling
- Oral capsules leverage the highly hydrophilic small‑molecule profile (very low LogP) and moderate aqueous solubility; formulations should limit exposure to metal ions due to tetracycline chelation.
- Intramuscular use requires solution or reconstitutable solid with controls on pH and metal content to maintain tetracycline stability.
- Tetracycline-class APIs are sensitive to moisture and light, so solid-state handling and packaging should minimize humidity and photodegradation.
Regulatory status
Supply Chain
| Supply chain summary | Lymecycline was originally developed by a single originator entity, with subsequent roles in finishing and distribution handled by additional packagers. The product is established primarily in European markets, with limited or no current presence in the United States but use in other regions. Patent protection has long expired, and the substance is already subject to mature generic competition. |
|---|
Safety
| Toxicity | The oral LD50 of lymecycline in rats is 3200 mg/kg.Overdoses with lymecycline are rare. In the case of an overdose, gastric lavage should be performed immediately. Provide supportive treatment and maintain fluid balance. |
|---|
- Rat oral LD50 is approximately 3200 mg/kg, indicating low acute toxicity but warranting controlled handling to limit high‑dose exposure
- Overdose cases are uncommon
- Maintain procedures to prevent accidental ingestion or significant systemic exposure
Lymecycline is a type of Tetracyclines
Tetracyclines are a widely used subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the treatment of various bacterial infections. They belong to the class of antibiotics and are characterized by their tetracyclic chemical structure. Tetracyclines exhibit broad-spectrum activity against both Gram-positive and Gram-negative bacteria, making them highly effective in combating a wide range of infections.
These APIs work by inhibiting protein synthesis in bacteria, thereby preventing their growth and reproduction. Tetracyclines bind to the bacterial ribosome, specifically the 30S subunit, and disrupt the addition of amino acids to the growing peptide chain, ultimately leading to bacterial cell death.
Due to their broad antimicrobial spectrum and efficacy, tetracyclines are utilized in the treatment of various infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, sexually transmitted diseases, and certain types of acne. Moreover, they have been used in the management of certain protozoal infections.
It is important to note that tetracyclines are subject to certain limitations and considerations. Their usage is contraindicated in pregnant women, children, and individuals with hepatic or renal impairments. Tetracyclines also exhibit photosensitivity, which may necessitate sun protection measures during treatment.
In summary, tetracyclines are a valuable subcategory of pharmaceutical APIs that offer broad-spectrum antimicrobial activity. Their effectiveness against a wide range of bacterial infections has made them indispensable in modern medicine, though their usage requires careful consideration of individual patient factors and potential side effects.
Lymecycline (Tetracyclines), classified under Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
Lymecycline API manufacturers & distributors
Compare qualified Lymecycline API suppliers worldwide. We currently have 5 companies offering Lymecycline API, with manufacturing taking place in 3 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| AXXO GmbH | Distributor | Germany | World | CEP, CoA, GMP, GDP, MSDS, USDMF | 243 products |
| Cipan | Producer | Portugal | Portugal | CEP, CoA, FDA, GMP | 7 products |
| Janssen Pharma | Producer | Belgium | Netherlands | CoA, GMP | 63 products |
| LGM Pharma | Distributor | United States | World | BSE/TSE, CEP, CoA, GMP, MSDS, USDMF | 441 products |
| Suanfarma | Distributor | Spain | Portugal | CEP, CoA, FDA, GDP, GMP, ISO9001, USDMF | 13 products |
When sending a request, specify which Lymecycline API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Lymecycline API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
Frequently asked questions about Lymecycline API
Sourcing
What matters most when sourcing GMP-grade Lymecycline?
Which documents are typically required when sourcing Lymecycline API?
Which manufacturers are known to produce Lymecycline API?
How can I request quotes for Lymecycline API from GMP suppliers?
Is a GMP audit report available for Lymecycline manufacturers?
How many suppliers offer Lymecycline API on Pharmaoffer?
Which countries are known to manufacture Lymecycline API?
Which certifications do suppliers of Lymecycline usually hold?
Technical
What is Lymecycline (CAS 992-21-2) used for?
Which therapeutic class does Lymecycline fall into?
What conditions is Lymecycline mainly prescribed for?
How does Lymecycline work?
What should someone know about the safety or toxicity profile of Lymecycline?
What are important formulation and handling considerations for Lymecycline as an API?
Is Lymecycline a small molecule?
Are there special stability concerns for oral Lymecycline?
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Lymecycline procurement?
Is Lymecycline included in the PRO Data Insights coverage?
Where can I access the API market report for Lymecycline?
